Cellanome has filed a notice of an exempt offering of securities to raise $75,930,476.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Cellanome is raising up to $75,930,476.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Cellanome
Cellanome develops advanced technologies that enable scientists to capture the dynamics of cells and their interactions over time by pairing longitudinal live-cell imaging with single-cell transcriptomics from the same cells. This integrated approach helps researchers discover functional phenotypes, connect cellular behavior with molecular state, study responses to perturbations over time, and generate rich multimodal datasets. Researchers can engage with Cellanome by implementing the R3200 platform in their lab, generating paired imaging and transcriptomic datasets through our assay services, or collaborating with our scientists to develop new applications and experimental workflows. Explore our technology, publications, and scientific resources, or contact our team to discuss how Cellanome can support your research.
To learn more, visit https://www.cellanome.com/
LinkedIn: https://www.linkedin.com/company/cellanome/
Contact:
Omead Ostadan, Chief Executive Officer
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.